3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Multiple Myeloma
5
Waldenstrom Macroglobulinemia
1
Recurrence
1
Precancerous Conditions
1
Neoplasms, Plasma Cell
1
Medulloblastoma
1
Mastocytosis, Systemic
1
Lymphoma, Mantle-Cell
1
Liver Neoplasms
1
Leukemia, Large Granular Lymphocytic
1
Ependymoma
1
Carcinoma, Hepatocellular
1
Interventions
Cyclophosphamide
15
Temozolomide
11
Vincristine
10
Magnetic Resonance Spectroscopy
10
Cisplatin
10
Specimen Handling
8
Radiotherapy
8
Etoposide
8
X-Rays
6
Phantoms, Imaging
6
Carboplatin
6
Nuclear Medicine Department, Hospital
5
Lomustine
5
Radiation
4
Platinum
4
Methotrexate
4
Irinotecan
4
Filgrastim
4
Biopsy
4
1,2-diaminocyclohexaneplatinum II citrate
4
etoposide phosphate
3
Thiotepa
3
Nivolumab
3
Granulocyte Colony-Stimulating Factor
3
Celecoxib
3
Bevacizumab
3
Automobiles
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Medulloblastoma
×
Thalidomide
×
1 year
×
Clear all
NCT01356290
2026-02-23
MEMMAT
Medical University of Vienna
Phase 2
Recruiting
232 enrolled